A study including over 86,000 patients found that heterozygotes with CHEK2 mutations, were significantly more likely to develop prostate cancer than noncarriers (OR 1.60; 95% CI, 1.00–2.56) [69]. This evidence concerns the gene CHEK2 and prostate cancer.